Together, we can make cancer care so much better
Management team
-
CEO & Founder
Having seen members members struggle with the challenges of poorly personalised cancer therapy, Toby founded Entia to change this. He received his PhD in Biomedical Physics from Imperial College London where he also holds an honorary lectureship. Toby has served as a board member at BIVDA and is a Blavatnik Enterprise Fellow of the Royal Academy of Engineering. He has overseen the growth of Entia from a university spin-out to an established market leader in oncology remote patient monitoring.
-
Head of Product
Tatiana is a dedicated product leader with a proven track record in developing health technology products from the ground up. She has successfully launched products and services across diverse markets, including both private and public healthcare settings in the UK, Europe, and Australia. With over 6 years of experience leading hardware and software product teams, she is a seasoned product manager and leader. Tatiana holds a degree in Biomedical Science from McGill University and an MSc in Global Health from University College London. Her academic and professional journey reflects her passion for using technology to drive improvements in the quality of care offered by health systems. She is excited to apply her expertise to oncology at Entia, where she aims to make a meaningful difference in supporting patients and providers with the management of cancer treatment.
-
Chief Operating Officer
Ed has built a career delivering challenging multi-disciplinary technology solutions. His experience spans a mix of engineering, science and software, having delivered many innovative projects, including ExoMars, James Webb Space Technologies, consumer products, analytics platforms, and advanced digital processing platforms. Ed enjoys reaching into his commercial and technical toolbox to help balance a wide range of stakeholders. He is passionate about solving challenging research and development problems, which is the driving force behind his role at Entia, as he brings the team together to ensure everyone has a united understanding of how we can effectively deliver value to cancer patients, in a fast-paced yet heavily regulated environment. Ed leads our balanced planning approach that allows us to adapt as we learn whilst delivering against our commitments. He enjoys challenging the traditional approach to delivering a medical device onto the market and prioritising effectively across our service, building systems that are ready to scale as we grow. Ed is excited to continue improving the lives of patients and clinicians with Entia's innovative work.
-
Head of Manufacturing
Torsten is a Manufacturing and R&D executive with 30+ years of experience in the medical device industry. He holds a Master's Degree in Mechanical Engineering from Denmark Technical University. He has been responsible for High volume medical device manufacturing on a global plan, which spans process development, new product integration, scale-up, automation and improvements which has given an extensive knowledge in Manufacturing processes for diagnostic devices and single-use consumables including FA and CE certifications. Further Torsten has been leading R&D for a global Medical Device brand and has been driving research and development of new medical device products to launch. Has a passion for scaleup and cost optimization of manufacturing.
-
Chief Financial Officer
-
CTO
Chris is our Chief Technology Officer and secret statistical robotics engineer. He has been around from the start of Entia, helping lead the advancement of our technology and product development. With over a decade of experience in medical devices and software, he has been challenging how medical devices are developed - trying to get innovations into the market quicker. His primary focus is on our AI, data, and technology architecture, which enables our leading oncology remote patient monitoring system. He cares deeply about elevating cancer care through cutting-edge product solutions. Chris holds a PhD in medical robotics from Imperial College London.
-
CCO
Mauricio recently joined our team as the Chief Commercial Officer, tasked with leading the commercial expansion of Entia. With over 18 years of experience in the healthcare industry, his career has encompassed both large multinational corporations and dynamic startups, offering him a well-rounded perspective. Mauricio's expertise spans various facets of healthcare, including medical devices, pharmaceuticals, healthcare provision, and health insurance. Throughout his international career in the UK, Europe, North America, and the Middle East, Mauricio has consistently excelled in formulating and executing commercial strategies as well as establishing successful partnerships. He holds a degree in industrial engineering and an MBA from INSEAD. Fluent in Spanish, English, and French, his multilingual skills contribute to his effectiveness in global business environments. We are thrilled to welcome Mauricio Karam to our team, where his wealth of knowledge and experience is poised to play a pivotal role in our ongoing success.
Board of directors
Natalie Douglas
Chair
Dr Toby Basey-Fisher
CEO & Founder
Joanna Smart
Non-Exec, BGF
Neil Cameron
Non-Exec, Parkwalk
Richard Gourlay
Observer, Sussex Place Ventures
Our journey so far
After years of co-development with thousands of cancer patients and healthcare professionals globally, we are now reshaping cancer therapy with Liberty
2015
2016
2021
2022
2023
Entia is founded by Dr Toby Basey-Fisher in response to seeing family members challenges through cancer therapy and his collaborations at Imperial College NHS Healthcare Trust
Entia establishes collaborations with two of Europe's leading cancer centres to develop Liberty. Our work with their patients and healthcare professionals provides unparalleled insights to guide development.
We spend 4 years in various pilots, trials and development activities, including supporting a number of NHS centres over Covid with remote patient monitoring solutions.
We receive backing from leading European investment funds BGF and Parkwalk to support the final stages of development and rollout of Liberty.
The Liberty blood count analyser is evaluated through four major trials involving 1,000s of patients and 5 NHS centres.
The Liberty full blood count analyser is approved for UK launch. In partnership with healthcare providers and leading life-science partners we're able to finally bring Liberty to patients.
Learn more about our story
Our Values
-
Make a diference
We're a mission driven company with a patient- centric mindset
-
Community
We value feedback. team building and celebration of achievements
-
Support and Balance
We appreciate empathy and psychological safety, inclusivity and balance
-
Knowledge and growth
We encourage skill sharing, curiosity and clarity